Valorization
The valorization activities of the Micalis Unit demonstrate a strong commitment to translating scientific research into commercially viable and clinically relevant biotechnological advancements. Micalis has been pivotal in founding and supporting multiple startup companies that leverage cutting-edge microbiological research to address pressing health, nutrition, and agricultural challenges.
Technological transfert
These initiatives reflect Micalis strategy of fostering innovation through entrepreneurship, multidisciplinary collaboration, and a commitment to addressing global health and environmental challenges. Each venture showcases Micalis ability to bridge scientific research with market needs, thereby enhancing the societal impact of academic discoveries.
Patents and Intellectual Property
Micalis has filed 56 patents in the last 5 years, underscoring its role as a hub of innovation.
These patents span various applications in microbiology, biotechnology, and related fields, illustrating the unit’s dynamic approach to research and development. Because patents are related to resarch teams, they are dispatched in this section.
Startup Ventures
Micalis scientists have not only pioneered research but have also played crucial roles in entrepreneurial ventures.
Maat-Pharma
Co-founded in 2014 by Joël Doré
This clinical-stage biotech company focuses on restoring microbiome symbiosis in oncology and treating Graft-versus-Host Disease (GvHD). Maat-Pharma has initiated a Phase 3 clinical trial for acute GvHD in March 2022 and utilizes its gutPrint® platform for drug candidate evaluation and biomarker identification.
Abolis Biotechnologies
Co-founded in 2014 by Jean-Loup Faulon
A spin-off from the BRS team, Abolis designs custom microorganisms for producing high-value molecules for sectors like health and cosmetics, integrating metabolic engineering with industrial scalability from the outset.
Exeliom Biosciences
Co-founded in 2016 by Philippe Langella and Harry Sokol
Specialized in immuno-inflammation and immuno-oncology, Exeliom uses the keystone commensal bacterium Faecalibacterium prausnitzii for developing therapies for inflammatory bowel diseases and enhancing immunotherapy efficacy in oncology.
Novobiome
Co-founded in 2020 by Hervé Blottière & Joël Doré
Develops Live Biotherapeutic Products (LBPs) targeting metabolic dysfunction-associated fatty liver diseases (MAFLD) and employs a multifaceted discovery platform for preclinical pharmaceutical development.
Carembouche
Co-founded in 2021 by Muriel Thomas
This company develops nutritious, probiotic-enriched treats for populations at risk of malnutrition, such as the elderly or those undergoing intensive medical treatments.
MicroXpace
Co-founded in 2022 by Luis Bermudez
Focuses on Alpha-Gal immunity-based solutions for agriculture and animal health, currently advancing to increased production and in vivo testing phases in collaboration with Lallemand Animal Nutrition.
Nodia Metabolics
Co-founded in 2024 by Christine Delorme, Vincent Juillard, Séverine Layec & Véronique Douard
This venture focuses on dietary supplements and metabolic regulation solutions, progressing from scientific discovery to patenting and commercialization phases with backing from regional innovation programs.
